Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS).

We recommend adjunctive therapy in selected patients with GCA (refractory or relapsing disease, presence of an increased risk for glucocorticoid-related adverse events or complications) using ...

In rhesus macaques that had received three 1 ml injections of adult rabbit brain in complete Freund's adjuvant (CFA), a dominant characteristic was the relapsing and remitting course of the ...